INVEST IN MED-X
$6.4M in Sales.
41 Markets to Go.
We’ve generated over $6 million in product sales over the past four years, and we’re just getting started. With the biopesticide market expected to triple by 20301, now’s the time to become a shareholder as we expand into 41 new international markets.
Top 3 Reasons to Invest in Med-X
Rapid Growth
6.4M in Sales
Med-X products have generated more than $6.4 million in sales in the last 4 years, thanks to strong retail partnerships and increasing demand for safer, natural pest control solutions.
World-Class Partners
.avif)
Nasdaq Here We Come
Meet MXRX
We’re planning a direct listing on the Nasdaq, and we’ve already reserved the ticker symbol "MXRX.” This is your opportunity to invest before it happens.*
Get our investor deck for an in-depth look at our potential in the $17.6B global pesticide market.
Long-term Pesticide Exposure Linked to Human Diseases
The negative effects caused by widespread pesticide use can be more dangerous as the pests themselves.2 The world is demanding a change. People and farmers desperately need safer, effective, alternative solutions to preserve food supplies and protect public health from pests but without the risks.
Simpler, Safer, More Effective Pesticides
More than addressing just one issue with a “green” product, we’ve developed and refined a portfolio of proprietary plant-based products. Third-party studies prove our flagship Nature-Cide pesticides outperform chemical-based products.
Proven Effectiveness
Third-Party Independent Study proves Nature-Cide outperforms traditional synthetic vector control products in some use cases using only essential oils from Clove, Cottonseed, Cedar, and Cinnamon.
Minimum Risk
Our solutions are safe to use around children, pets, and the environment and are a fully sustainable professional approach to all types of pest management.
Complete Solution
One product line manages multiple pests in all settings. Less need to carry dozens of products for an operator. Same cost to use all-natural solutions.
National Reach & Rapid Growth
Our Nature-Cide product line is already available through major ecommerce retailers like Amazon, Walmart, and Kroger. These partnerships have helped drive $6.4 million in product sales over the past four years, and the products continue to earn rave customer reviews.
Our Global Vision Is a $17.6B Opportunity
We’ve secured an exclusive agreements with Target Specialty Products, Ensystex and Preserve to introduce the Nature-Cide product line into 41 new markets, including but not limited to:
- Australia
- New Zealand
- Southeast Asia
- Caribbean Islands
- Africa
- Mexico
- And more
The global biopesticide market is expected to grow ~3X by 2030, from $5.8 billion in 2022 to an impressive $17.6 billion by 20301. We expect pesticide bans and other regulatory actions around the world to fuel our vision of Nature-Cide as the world’s leading “clean” pest control product.
Our Vision for the Future
Once we list and get access to growth capital, management plans to launch its M&A strategy to bolster capitalization after the public market listing process*.
Get our investor deck for an in-depth look at our potential in the $17.6B global pesticide market.
Latest Video Update: May 2025
Watch our most recent company update from CEO, Matthew Mills to gain valuable insights into our company and this exciting investment opportunity. This is a fantastic chance to learn directly from our leadership team and understand our vision and strategy. Stay tuned for future updates that will be posted here in the future.
Get Updates Straight to Your Inbox.
Recent News
Med-X Partners with Anasac Ambiental for Nature-Cide Product Distribution in South America
Med-X Secures Coveted OMRI Listing for Nature-Cide All-Purpose Commercial Concentrate to Allow for Use in Certified Organic Food Processing Facilities
Med-X to Showcase a Newly Developed Nature-Cide Rat & Mouse Control Product at PestWorld 2024 in Denver Colorado from October 22-25
Med-X Announces Registration of the Nature-Cide All-Purpose Commercial Concentrate Product in Mexico
Experienced Leadership Team
Operations Professional, Oversaw over $200M Revenue Book in Prior Role.
Clinical Investigator for Big Pharma and Family Physician for more than 24 years.
Finance Professional with Over 35 Years of Public Company Experience.
E-Commerce Professional with Significant Experience Scaling Companies.
Project Management and Human
Resources Professional.
Internal and Osteopathic Medicine.
Neurologist and Scientist.
Financial and Investment
Banking Specialist
Scientist and Mathematician.
FAQs
You can review all of Med-X’s SEC Filings, including the offering circular for the Regulation A+ offering, here.
The offering price is $4 per share and the minimum investment amount for this round is $600.
Click “Invest Now” anywhere on this site, or follow this link: invest.medx-rx.com/checkout. You will be directed to view the subscription agreement and complete an investment.
Investors can purchase shares via credit card, bank-to-bank payments, or express wires (reconciled in real-time).
This offering is open to both accredited and non-accredited investors. If you are a non-accredited investor, please note that you cannot invest more than 10% of the greater of your annual income or net worth.
According to the SEC, an individual accredited investor can be defined as the following:
An accredited investor, in the context of a natural person, includes anyone who:
- earned income that exceeded $200,000 (or $300,000 together with a spouse or spousal equivalent) in each of the prior two years, and reasonably expects the same for the current year, OR
- has a net worth over $1 million, either alone or together with a spouse or spousal equivalent (excluding the value of the person’s primary residence), OR
Additionally, an accredited investor as an entity can be defined as the following:
- A trust is considered to be an accredited investor if its assets exceed $5 million, it is not created to purchase the securities and it is directed by a sophisticated person; or
- An entity is an accredited investor if its investment exceeds $5 million and it is not created to purchase securities.
- An entity in which all equity owners are accredited investors.
If your credit card payment was declined, please call your credit card provider to pre-authorize the transaction. Additionally, if your bank-to-bank transfer via ACH has failed, it is recommended that you contact your bank for more information.
To change your email address, please navigate to the top-right corner of your Dashboard. Within your profile settings, you can change the email address associated with your account. If you would like to merge investments to a pre-existing account, under a different email address, please contact info@dealmaker.tech for assistance. Please specify the applicable email addresses to be changed. For investor security, you will be asked to verify that you have access to the applicable accounts.
You can specify whether you are investing as an individual, or as a corporation/trust/custodial. Upon selecting any of the non-individual options, you will be prompted to enter relevant information and populate your subscription agreement accordingly.
1) Funding Processed:
Your investment funding status will update upon receipt of your funds. If paying by bank-to-bank transfer, your payment will initially appear as pending, and will either clear or fail within five business days. If paying by wire domestically, your wire should be reconciled within one business day. International wires vary. Once funds are received, it can take approximately 1-2 weeks.
2) Identity Processed:
In some instances, we may reach out to you requesting additional information in order to verify your identity & finish processing your investment, which may increase the overall processing time.
3) Subscription Confirmation:
Once your investment has been fully processed and confirmed, you will receive a notification when your subscription agreement has been accepted. Subsequently, you will receive a digital confirmation of the security holdings. If 3 weeks pass by and you do not receive any information from us, please email us at investorrelations@medx-rx.com We may still require additional information. We recommend you check your spam folder first for any email communications!
Please note that if your securities are being distributed through the DealMaker platform, you will receive a digital certificate or DRS statement from the transfer agent, uploaded to your investment portal. No paper share certificates are distributed via DealMaker.
For further information regarding DRS statement distribution, please contact our investor support team at: investorrelations@medx-rx.com.
For more information regarding your investment in this offering, please contact our investor support team at: investorrelations@medx-rx.com
You can search the DealMaker knowledge base for more information here, or contact investor support at investorrelations@medx-rx.com.
Yes. Securities sold in a Regulation A+ offering are not considered “restricted securities” under Securities Act Rule 144. As a result, sales of securities by persons who are not affiliates of the issuer are not subject to any transfer restrictions.
Investors need to check with a brokerage account representative to determine whether their provider will allow for the securities to be (i) directly deposited to a brokerage account or (ii) transferred into such account at a later day. The policies may vary between different providers.